IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response

被引：68

作者：

Leyva, L

Fernández, O

Fedetz, M

Blanco, E

Fernández, VE

Oliver, B

León, A

Pinto-Medel, MJ

Mayorga, C

Guerrero, M

Luque, G

Alcina, A

Matesanz, F

机构：

[1] Hosp Civil, Lab Invest, Malaga 29009, Spain

[2] Hosp Carlos Haya, Serv Neurol, Inst Neurociencias Clin, Malaga 29010, Spain

[3] Hosp Clin San Cecilio, Granada 18012, Spain

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2005年 / 163卷 / 1-2期

关键词：

type I interferon receptor; polymorphism; multiple sclerosis; association; treatment;

D O I：

10.1016/j.jneuroim.2005.02.010

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We investigated the role of three polymorphisms in the IFNAR1 (SNPs 18417 and -408) and IFNAR2 (SNP 11876) genes in multiple sclerosis (MS) susceptibility and in the IFN treatment response in a group of 147 patients and 210 controls undergoing interferon therapy during the last 2 years. Only the 18417 and the 11876 SNPs showed an association with disease susceptibility (p = 0.001 and 0.035, respectively) although no differential genotype distribution were observed between interferon responders and non-responder MS patients. No alteration of the expression level of IFNAR-1 was observed with respect to the -408 genotypes or to interferon treatment response. These data suggest a role for the IFNAR pathway in susceptibility to MS. (C) 2005 Elsevier B.V. All rights reserved.

引用

页码：165 / 171

页数：7

共 30 条

[1] Interferon-alpha receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in The Gambia [J].